Model N Inc. provides revenue management solutions for life sciences and technology companies including applications for configure, price, quote (CPQ), rebates management and regulatory compliance. The company is accelerating its transition of revenue management to cloud. The company is making steady progress in its transformation to a Software-as-a-Service based model. The company provides Revenue Cloud for Pharma, Med Tech, High-Tech Manufacturing and Semiconductors & Components. Model N's revenue cloud offerings provide higher Return on Investment as well as plug gaps in the end-to-end revenue management process that legacy systems fail to do. Revenue Cloud suite is a software-as-a-service based subscriptions tool developed to automate processes of Revenue Management lifecycle. The suite includes products for CPQ, Contract Lifecycle Management and Rebates Management....
+See MoreSharpe-Lintner-Black CAPM alpha (Premium Members Only) Fama-French (1993) 3-factor alpha (Premium Members Only) Fama-French-Carhart 4-factor alpha (Premium Members Only) Fama-French (2015) 5-factor alpha (Premium Members Only) Fama-French-Carhart 6-factor alpha (Premium Members Only) Dynamic conditional 6-factor alpha (Premium Members Only) Last update: Saturday 25 April 2026
2018-01-05 07:37:00 Friday ET

Warren Buffett cleverly points out that American children will not only be better off than their parents, but the former will also enjoy higher living stand
2020-03-26 10:31:00 Thursday ET

The unique controversial management style of Steve Jobs helps translate his business acumen into smart product development. Jay Elliot (2012) Leading
2017-11-03 06:41:00 Friday ET

Broadcom, a one-time division of Hewlett-Packard and now a semiconductor maker whose chips help power iPhone X, has announced its strategic plans to move it
2018-02-15 07:43:00 Thursday ET

Fed minutes reflect gradual interest rate normalization in response to high inflation risk. FOMC members revise up the economic projections made at the Dece
2018-10-15 09:33:00 Monday ET

Several pharmaceutical companies now switch their primary focus from generic prescription drugs to medical specialties such as cardiovascular medications an
2019-09-09 20:38:00 Monday ET

Harvard macrofinance professor Robert Barro sees no good reasons for the recent sudden reversal of U.S. monetary policy normalization. As Federal Reserve Ch